Wells Fargo resumed coverage of Nevro (NVRO) with an Equal Weight rating and $5 price target Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro downgraded to Underweight from Equal Weight at Morgan Stanley
- Nevro announces publication of new data on Nevro1 SI Joint Fusion System
- Nevro Corp. Reports Strong Q3 2024 Financial Performance
- Nevro Corp’s Market Cap Challenges: Impairment Risks and Investor Concerns
- Nevro rises 28.2%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
